Development
Emergent BioSolutions Inc.
EBS
$6.29
$0.050.80%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 276.60M | 270.50M | 337.10M | 165.10M | 330.20M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 276.60M | 270.50M | 337.10M | 165.10M | 330.20M |
| Cost of Revenue | 221.40M | 180.10M | 213.40M | 192.20M | 215.90M |
| Gross Profit | 55.20M | 90.40M | 123.70M | -27.10M | 114.30M |
| SG&A Expenses | 89.70M | 86.00M | 92.20M | 100.50M | 93.40M |
| Depreciation & Amortization | 16.20M | 16.30M | 16.10M | 17.00M | 17.90M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 327.30M | 282.40M | 321.70M | 309.70M | 327.20M |
| Operating Income | -50.70M | -11.90M | 15.40M | -144.60M | 3.00M |
| Income Before Tax | -54.50M | -265.90M | -249.70M | -161.10M | -61.40M |
| Income Tax Expenses | -5.00M | -2.50M | 14.90M | 21.90M | 5.60M |
| Earnings from Continuing Operations | -49.50M | -263.40M | -264.60M | -183.00M | -67.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.50M | -263.40M | -264.60M | -183.00M | -67.00M |
| EBIT | -50.70M | -11.90M | 15.40M | -144.60M | 3.00M |
| EBITDA | -22.00M | 15.00M | 47.40M | -111.10M | 24.60M |
| EPS Basic | -0.95 | -5.08 | -5.22 | -3.65 | -1.34 |
| Normalized Basic EPS | -0.74 | -0.42 | -0.21 | -1.96 | -0.04 |
| EPS Diluted | -0.95 | -5.08 | -5.22 | -3.65 | -1.34 |
| Normalized Diluted EPS | -0.74 | -0.42 | -0.21 | -1.96 | -0.04 |
| Average Basic Shares Outstanding | 51.90M | 51.80M | 50.70M | 50.20M | 49.90M |
| Average Diluted Shares Outstanding | 51.90M | 51.80M | 50.70M | 50.20M | 49.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |